Aura Biosciences (AURA) vs Nuvectis Pharma (NVCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nuvectis Pharma (NVCT) has outperformed Aura Biosciences (AURA) over the past year, gaining 232.1% versus a gain of 12.2%. Aura Biosciences is the larger company by market cap ($669.9 million vs $662.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AURA | NVCT |
|---|---|---|
| Share price | $6.46 | $20.29 |
| Market cap | $669.93M | $662.35M |
| 1-day change | +4.70% | +1.30% |
| YTD return | +18.53% | +168.74% |
| 1-year return | +12.15% | +232.08% |
| EPS (TTM) | $-1.75 | $-1.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.54 | $29.28 |
| 52-week low | $4.73 | $5.55 |
| Distance from 52-week high | -32.25% | -30.69% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +156.97% | +74.47% |
| Average volume | 740.43K | 217.91K |
| Shares outstanding | 103.70M | 32.64M |
| Employees | 113 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVCT has outperformed AURA by 219.9 percentage points over the past year.
About Aura Biosciences
AURA stock →Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees
About Nuvectis Pharma
NVCT stock →Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
AURA vs NVCT FAQ
Which is bigger, Aura Biosciences or Nuvectis Pharma?
Aura Biosciences (AURA) is larger, with a market capitalization of $669.93M compared with $662.35M for Nuvectis Pharma (NVCT).
Which stock has performed better over the past year, AURA or NVCT?
NVCT returned +232.08% over the past 12 months, compared with +12.15% for AURA (price return, excluding dividends). Past performance does not predict future results.
Are Aura Biosciences and Nuvectis Pharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Aura Biosciences and Biotechnology: Pharmaceutical Preparations for Nuvectis Pharma.